![]() Again, this is not the long-term plan of managing the immune system aspect of this therapy. Because these are “allogeneic” cells-which means they come from outside the patient’s body-the patient must also undergo immunosuppression therapy to protect these transplanted cells from their body’s immune system. VX-880 works by essentially replacing the damaged insulin-producing cells in a person with type 1 diabetes with healthy transplanted beta-cells. ![]() The ability to manufacture transplantable insulin-producing cells eliminates the obstacle of relying on organ donors, making VX-880’s success a noteworthy moment in history. VX-880 is a manufactured proprietary stem cell therapy product that aims to restore endogenous insulin production and stabilize blood sugar levels. Here, we’ll take a closer look at the latest results, the FDA’s instructions to pause the study and the future of immunosuppression for the long-term success of VX-880. ![]() Meanwhile, the Canadian-based trial on VX-880 is still active. Fortunately, the reasoning for pausing the study appears to be a minor bump in the road: the FDA feels there is “insufficient information” to support increasing the trial participants’ dosages of VX-880. Vertex, however, is confident it will find better ways to manage the immune system around its proprietary product.Īdditionally, the Food and Drug Administration (FDA) has suddenly placed the U.S.-based clinical trial on hold. Still currently in Phase 1/2 of its clinical trial, there is still one caveat to its success: the patient requires immunosuppression therapy to sustain their insulin production. made headlines with earlier results of the same trial: the same patient had experienced a 91% reduction in their daily need for exogenous insulin at day 90. This means the patient no longer requires exogenous (external) insulin doses and is producing enough endogenous (internal) insulin to maintain normal blood sugar levels at day 270 of the trial. The first patient dosed with VX-880-a stem cell-derived potential therapy to treat type 1 diabetes-has achieved groundbreaking insulin independence at day 270 with an HbA1c of 5.2 percent, according to a recent press release. Stem Cell Therapy for Type 1 Diabetes Reduced Patient’s Insulin Needs by 91%.Read past coverage on Vertex Pharmaceuticals’ stem cell therapy: For more information on type 1 diabetes research visit our research portal to learn more about getting involved with clinical trials, click here. Editor’s Note: The news shared below is from a recent and promising clinical trial.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |